home / stock / vetof / vetof news
Vetoquinol press release ( OTCPK:VETOF ): Q3 Revenue of €134M (+1.3% Y/Y) down 4.5% at constant exchange rates. On a reported basis, Europe declined by 8% in the third quarter; the Americas and Asia/Pacific each grew by 10%. "...
VETOQUINOL ORD press release (OTC:VETOF): Q1 sales of €135M (+5.5% Y/Y). Essential products sales were €77M (+8.1%). For further details see: VETOQUINOL ORD reports Q1 results
VETOQUINOL ORD (OTC:VETOF): 1H Net income of €36.2M Revenue of €255.3M (+30.2% Y/Y) Press Release For further details see: VETOQUINOL ORD reports 1H results
The physiological and psychological benefits that pets give us are meaningful. COVID has amplified our appreciation of this. Anticipating 6% annual growth until 2030 may be conservative, even across developed markets. Impressive margins and high growth is apparent across consumabl...
VETOQUINOL ORD (VETOF): FY Net income of €19.2MRevenue of €427.5M (+8.0% Y/Y)Press Release For further details see: VETOQUINOL ORD reports FY results
Vetoquinol ([[VETOF]]) acquires the Drontal and Profender product families, the intellectual property, registrations and other rights from Elanco Animal Health for the Australian market.“The acquisition of these strong brands for the Australian market confirms our ambition to become a ...
VETOQUINOL ORD (VETOF): Q3 Revenue of €114.5M (+14.4% Y/Y)Press Release For further details see: VETOQUINOL ORD reports Q3 results
Vetoquinol ( OTC:VETOF ): 1H Net income of €12.8M. More news on: Vetoquinol, Earnings news and commentary, Consumer stocks news, , Read more ...
Vetoquinol ( OTC:VETOF ): FY EBITDA of €60.40M. Revenue of €367.9M (+3.2% Y/Y) Press Release More news on: Vetoquinol, Earnings news and commentary, Consumer stocks news, ,